Cadrenal Therapeutics, Inc. (NASDAQ:CVKD – Get Free Report) CEO Quang Pham sold 3,298 shares of the stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $5.28, for a total value of $17,413.44. Following the completion of the transaction, the chief executive officer directly owned 185,150 shares in the company, valued at approximately $977,592. This represents a 1.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Cadrenal Therapeutics Stock Performance
CVKD stock opened at $4.96 on Friday. Cadrenal Therapeutics, Inc. has a fifty-two week low of $4.21 and a fifty-two week high of $15.99. The business’s 50-day moving average is $5.31 and its two-hundred day moving average is $7.18. The company has a market cap of $14.24 million, a price-to-earnings ratio of -0.88 and a beta of 1.81.
Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.04) EPS for the quarter, topping analysts’ consensus estimates of ($1.51) by $0.47. Equities analysts predict that Cadrenal Therapeutics, Inc. will post -5.52 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on Cadrenal Therapeutics
Institutional Trading of Cadrenal Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of CVKD. DRW Securities LLC bought a new stake in Cadrenal Therapeutics during the 4th quarter valued at approximately $171,000. Citadel Advisors LLC bought a new stake in Cadrenal Therapeutics during the 3rd quarter valued at approximately $274,000. Geode Capital Management LLC raised its stake in Cadrenal Therapeutics by 14.3% during the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after purchasing an additional 1,818 shares during the period. Finally, JPMorgan Chase & Co. bought a new stake in Cadrenal Therapeutics during the 3rd quarter valued at approximately $103,000. Hedge funds and other institutional investors own 7.92% of the company’s stock.
About Cadrenal Therapeutics
Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Featured Articles
- Five stocks we like better than Cadrenal Therapeutics
- Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem
- These 3 Software Stocks Are Buying Back Shares Hand Over Fist
- Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%
- MongoDB’s AI Advantage Is Starting to Show Up in Results
Receive News & Ratings for Cadrenal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
